声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。就在一众药企为年度订单能否突破十亿大关而奋力拼搏之时，行业巨头“药明系”抛出的的一颗深水炸弹，重新定义了市场的想象空间。近日，药明康德、药明生物与药明合联相继交出的半年度成绩单显示，“药明系”三家企业在手订单总额已悄然突破惊人的2000亿元大关。是如何...
Source Link声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。就在一众药企为年度订单能否突破十亿大关而奋力拼搏之时，行业巨头“药明系”抛出的的一颗深水炸弹，重新定义了市场的想象空间。近日，药明康德、药明生物与药明合联相继交出的半年度成绩单显示，“药明系”三家企业在手订单总额已悄然突破惊人的2000亿元大关。是如何...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.